Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

T cell therapies.

S Gottschalk1, C M Bollard, K C Straathof

  • 1Center for Gene and Cell Therapy, Baylor College of Medicine, 6621 Fannin Street MC 3-3320, 77030 Houston, USA. smg@bcm.edu

Ernst Schering Foundation Symposium Proceedings
|September 11, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Practical Guide to 16S rRNA Microbiome Analysis in Musculoskeletal Disorders.

Methods in molecular biology (Clifton, N.J.)·2023
Same author

The Effect of Number of Gait Cycles on Principal Activation Extraction.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2021
Same author

Evidence review of physical distancing and partition screens to reduce healthcare acquired SARS-CoV-2.

Infection prevention in practice·2021
Same author

Protecting the Microbiota.

The Journal of infectious diseases·2021
Same author

Anticancer innovative therapy: Highlights from the ninth annual meeting.

Cytokine & growth factor reviews·2019
Same author

Curative Radiotherapy for Lung Cancer in the UK: International Benchmarking.

Clinical oncology (Royal College of Radiologists (Great Britain))·2019

T cell therapies show promise for treating cancers and viral diseases. This review focuses on Epstein-Barr virus (EBV)-specific cytotoxic T cells (CTL) and strategies to enhance their anti-tumor activity for EBV-associated malignancies.

Area of Science:

  • Immunotherapy
  • Oncology
  • Virology

Background:

  • T cell therapies are emerging treatments for malignancies and viral diseases.
  • Early T cell therapy research focused on unmanipulated T cells post-allogeneic stem cell transplantation.
  • Recent advancements explore antigen-specific T cells for targeted therapy.

Purpose of the Study:

  • To review clinical experience with polyclonal Epstein-Barr virus (EBV)-specific cytotoxic T cells (CTL).
  • To discuss strategies for enhancing the anti-tumor activity of EBV-specific CTL.
  • To explore the implications for broader T cell therapies in human tumors.

Main Methods:

  • Review of clinical data on EBV-specific CTL therapy.
  • Analysis of strategies to augment CTL anti-tumor efficacy.

Related Experiment Videos

  • Discussion of potential applications in broader oncology.

    • Main Results:

    • Clinical experience with EBV-specific CTL for EBV-associated malignancies has been documented.
    • Various strategies are under investigation to improve CTL anti-tumor activity.
    • Successful enhancement strategies could advance T cell therapies for diverse cancers.

    Conclusions:

    • Polyclonal EBV-specific CTL represent a viable therapeutic approach for EBV-associated malignancies.
    • Optimizing CTL anti-tumor activity is crucial for treatment efficacy.
    • Advances in EBV-specific CTL therapy hold promise for a range of human tumors.